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Goldhaber has described a transplantable mouse fibrosarcoma which enhances 
the  resorption of bone in  tissue culture  (2,  3).  When fragments  of the tumor 
(HSDM1)  were placed in the same culture vessel with mouse calvaria, marked 
resorption of  the  bone  was  observed.  Fragments  of HSDM1  tumor  could  be 
cultured  alone,  and  the  medium  from  such  explants  also  stimulated bone 
resorption when it was added to calvaria in organ culture. These findings sug- 
gested that the tumor was synthesizing and secreting a  bone resorption-stimu- 
lating  factor.  Results  of  our  previous  experiments  revealed  that  the  factor 
could be extracted from the tumor  tissue and recovered from the medium  of 
HSDM1  cells grown  in  monolayer culture  (1).  Of particular interest was  the 
finding that  the HSDM1  factor could be extracted into  organic solvents,  and 
that  it had several chemical and biological properties of a  prostaglandin. 
We  have  recently  reported  that  HSDM1  cells  in  culture  synthesize  and 
secrete large amounts of prostaglandin E2 (4). In the present report, we wish to 
present evidence that leads us to conclude that the bone resorption-stimulating 
factor produced by the HSDM1 tumor is prostaglandin Ee. 
Materials and Methods 
The HSDM1  Tumor.--A  fibrosarcoma  was induced in a  Swiss albino mouse  by subcu- 
taneous implantation of a Millipore filter (5, 6). The tumor has been passed serially  in mice of 
the same strain for more than a decade.  Excised tumor from a donor mouse is minced into 
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small  fragments which are  injected subcutaneously  in  new  host  animals.  At  least  75%  of 
injected mice develop palpable tumors within  1 wk, and these are transplanted at  approxi- 
mately 3-wk intervals. In the experiments reported here, tumors were carried exclusively in 
male mice, although animals of both sexes can serve as host. 
Establishment  of HSDM1  Tumor Cells in Monolayer  Culture.--The  procedures used were 
similar to those reported in detail previously from this laboratory for the establishment of rat 
pituitary tumor cells in culture (7). In brief, a tumor was removed aseptically, minced with fine 
scissors, and  the cell  aggregates dispersed with Viokase  and plated  in plastic Petri  dishes 
(Falcon Plastics, Division B-D Laboratories, Inc., Los Angeles, Calif.) in Ham's F  10 medium 
(8)  supplemented with 15% horse serum and 2.5% fetal calf serum. Cultures were incubated 
at 37°C in a humidified atmosphere of 5% CO2 and 95% air. The tumor cells adapted readily 
to the conditions of primary culture without resort to the serial culture to animal enrichment 
technique previously described  (7).  Primary  cultures were subcultured  by  treatment  with 
Viokase, and the cells diluted 1 : 5 to 1: 40 and replated in fresh dishes. Such cultures have been 
serially propagated, with subculture every 10-20 days, for 41 months without signs of senes- 
cence, as evidenced by a  decreased rate of cell growth or loss of ability to produce the bone 
resorption-stimulating factor. 
Five clonal strains  of HSDM1  cells were derived by plating single cells in  Microtest II 
tissue culture plates  (Falcon) with 100/zl of cell culture medium. Such single ceils also grew 
well, and each ceil gave rise to a colony which was harvested, subcultured, and propagated in 
Petri  dishes  as  a  clonal  strain.  The  five  clones  are  designated  HSDM~Ca,  HSDMaC2, ... 
ItSDM1Cs. They have been in continuous culture for 11 months. 
All clonal strains as well as the uncloned cultures secrete the bone resorption-stimulating 
factor into the culture  medium  (see below).  To demonstrate that the cells in  culture  (both 
uncloned  and  clonal strains)  were indeed tumor cells, we harvested cells from monolayers 
(7, 9) and injected 106 cells per animal into groups of four to six male Swiss albino mice.  All 
injected mice developed tumors within less than  10 days. The culture-derived tumors were 
excised and extracted, and the extracts were assayed biologically (see below) and were found 
to contain the bone resorption-stimulating factor. The cycle of transfer of tumor cells from 
mouse to culture was then successfully repeated again. 
In certain experiments, HSDM1 cells were maintained in serum-free, synthetic F  10  me- 
dium alone. 
Extraction  and  Fractionation  of  Tumors  and  Ceil Culture  Medium.--Excised  HSDM1 
tumors were homogenized for 30  sec in  Gey's balanced salt  solution  (3  ml/g)  in  a  Waring 
Blendor at room temperature. The insoluble material was removed by centrifugation (10,000 
g at 4°C for 20 rain)  and the supernatant solution was designated, crude extract. The crude 
extract was placed in a  boiling water bath and stirred for 15  rain, and the large precipitate 
which formed was removed by centrifugation (10,000 g at 4°C for 30 min). The supernatant 
solution was fracdonated sequentially on columns of Sephadex G-50 and then G-10 using 0.2 z~ 
ammonium acetate, pH 4.7, as the solvent  (1).  Fractions collected from the column eluates 
were pooled, diluted with distilled water, and lyophilized. The residue was redissolved in water 
and lyophilized again to eliminate the bulk of the ammonium acetate. The final powder was 
weighed and dissolved in Gey's balanced salt solution for assay in the bone culture system. 
Certain aqueous solutions or extracts were acidified to pH 3.5-3.7 with citric or acetic acid 
and were extracted three times at room temperature with 1.5 volumes of fresh diethyl ether. 
The ether extracts were combined and dried under a stream of nitrogen gas at 40°C,  and the 
residue was taken up in Gey's balanced salt solution for bioassay in the bone culture system or 
for radioimmunoassay for prostaglandins (see below). 
Medium from HSDMa  and  control ceils in culture was extracted with ether exactly  as 
described above. 
Assay for Bone Resorption-Stimulating  Activity.--Initial  experiments were performed using 
the mouse calvaria bone-resorbing culture system of Goldhaber  (10).  Groups of four or five 
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contained one group of control bones and two groups of bones treated with standard mate- 
rials, either parathyroid hormone (PTH) 1 (Eli Lilly and Co., Indianapolis, Ind.; parathyroid 
extract,  USP,  100  units/ml)  or prostaglandins,  1 at  two dose levels.  Medium was changed 
every 2 days, and the extent of bone resorption was estimated semiquantitatively by micro- 
scopic examination of the cultures. Each bone was given a resorption score (index of resorption) 
on a scale of 0-6, where 6 was complete loss of mineral. At the end of each experiment, after 
6-10 days of culture, the mineral remaining in the bone was stained by yon Kossa's method. 
In order to make the bone-resorption assay more efficient and quantitative, it was modified 
for later experiments as follows.  1 day old mice were injected subcutaneously or intraperi- 
toneally with 10 #Ci of 45Ca. 4 days later the calvaria were removed and fixed  to cover slips 
exactly as in the unlabeled bone culture method described above. All bones were placed in 
culture for an initial 24 hr period without specific treatment. This "washout" period was used 
to allow release of the most rapidly exchangeable 45Ca in the bone. The washout medium was 
recovered and counted and the bones were then divided randomly into control, standard, and 
treatment groups of three to five bones each. This period was designated, zero time. Fresh 
medium containing control, standard, or test substances was added to appropriate groups of 
bones. 24 hr later an aliquot (25-50 #1) of medium was taken for determination of 45Ca content 
by liquid  scintillation counting. The experiment was terminated at  48  hr  (after 2  days of 
treatment) and the total accumulated 45Ca radioactivity in medium again determined. The 
results are expressed as counts per minute 45Ca per milliliter of medium at 24 and 48 hr, and 
a mean value and standard error were calculated for each time interval for each experiment 
(see statistical method below). Measurements of 4~Ca in the medium from each bone during 
the washout period and in the residual bone mineral at  the end of the experiment  (after 
hydrolysis in 98% formic acid) indicated an acceptable degree of uniformity of labeling be- 
tween bones (_P >  0.05 for the difference between bones). 
Radioimmunoassay  of  Prostaglandlns.--Prostaglandins  were  assayed  immunologically 
using the technique of Levine, Gutierrez-Cernosek, and Van Vunakis (11). Where indicated, 
samples were treated with NaOH immediately before assay (pH 12.0-12.5  at 100°C for 5-10 
rain) to convert PGE to PGB.  1  All assays were performed with antiserum to PGB1 (11). 
For analysis of prostaglandins in serum,  the extraction and concentration procedure of 
Gutierrez-Ceruosek, Morrill, and Levine  (12) was used. Blood was drawn from control or 
HSDM1 tumor-bearing mice (2-3 wk after transfer of tumor) by cardiac puncture with special 
care  to avoid hemolysis or tissue fluids.  Samples from individual mice  (about  1 ml)  were 
incubated at 37°C for 30-40 rain to accelerate clot formation. Clots were removed by forceps, 
and the serum was separated from residual erythrocytes by centrifugation (5000 g at room 
temperature for 20 rain). Calcium levels in serum were determined immediately (see below), 
and the remaining serum was frozen at  --70°C for 1-7 days before extraction for assay of 
prostaglandins. Sera from individual mice were combined into pools of 3.5-5.0 ml, extracted 
with methylal-ethanol, and concentrated as previously described for human sera (12). 
Analysis of Serum Calcium.--Serum from individual control or tumor-bearing mice was ob- 
tained as described above. The concentration of calcium in  serum was determined by the 
method of Copp (13). 
Statistical  Method.--The  serum calcium and 45Ca data in each experiment were subjected 
to an analysis of variance. The standard errors (SE)  were calculated from the residual error 
term of each analysis. 
Materials.--Indomethacin  (lot No. 35811) was a gift from Merck, Sharp & Dohme Research 
Laboratories, West Point, Pa.  The nonradioactive prostaglandins were  obtained  from Dr. 
John  Pike  of The  Upjohn Co.,  Kalamazoo, Mich. The prostaglandins-3H and  45Ca were 
purchased from New England Nuclear Corp., Boston, Mass. 
1 Abbreviations  used in this  paper:  PGE, PGA, and PGB for prostaglandins of the E, A, 
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RESULTS 
Eject of Extracts of the HSDM1 Tumor on Bone Resorption in Tissue Culture.- 
Crude aqueous extracts of the HSDM1 tumor were tested for bone resorption- 
stimulating activity initially in  the  semiquantitative culture system.  Fig.  1 
shows the results obtained with three dose levels of crude extract.  Concentra- 
tions of 800 and 2400 #g of solid/ml culture medium clearly stimulated bone 
resorption. Similar extracts of normal control mouse liver, kidney, and muscle, 
or of three other transplantable tumors (adrenal, pituitary, and liver) did not 
stimulate bone resorption. Fractionation of the crude extract by precipitation 
of protein by heating and sequential gel filtration on columns of Sephadex G-50 
and  G-10  gave  material  which  was  enriched  in  bone  resorption-stimulaing 
activity by a factor of at least 1000-fold (1). This material stimulated resorption 
at dose levels of less than 1 #g of solid/ml medium (Fig. 2). The specific bio- 
FIG. 1.  Appearance of stained (von Kossa) bones (four per group) at the end of a 7 day 
period in culture. Control bones on the left show little loss of mineral  (black stain). On the 
right is shown the loss of mineral (loss of black staining material) induced by 800 and 2400 
#g/ml medium of a crude aqueous extract of HSDM1 tumor tissue. 
Fro. 2.  Effects of fractionated HSDM1 tumor extract on bone resorption. Control bones 
are on the left. The materials designated 93-II1 and 93-V are fractions from gel filtration on a 
column of Sephadex G-10 (1). Fraction 93-IIi is material from the void volume of the column. 
It did not stimulate  bone resorption at a dose level of 30 /~g  of solid/ml culture medium. 
Fraction 93-V was from the retarded portion of the  chromatogram.  Enhancement  of bone 
resorption was seen clearly at 4.0 and 0.4/~g of solid/ml. TASHJIAN~  VOELKEL,  LEVINE,  AND  GOLDtIABER  1333 
logical activities of several bone resorption-stimulating factors were compared. 
The results, summarized in Table I, show that the HSDMI factor is as active 
as parathyroid horone and prostaglandins of the E  series. 
In order to demonstrate  that  the factor extracted from  the HSDM1  tumor 
was produced by viable tumor cells  and was not a  product of cell necrosis, we 
established dispersed cell cultures from the tumor and examined  the medium 
for bone  resorption-stinmlating activity. 
TABLE 1 
Comparison of Specific Activities of Several Bone Resorption-Stimulating Factors 
Concentration needed to give a bone 
Factor  resorption index of 3.0* 
#g/ml medium 
ParathyroM hormone  0.05 
Vitamin D2  50 
25-OH vitamin D8  5 
Dibutyryl-cAMP  50 
PGE1  0.03 
PGE~  0.03 
PGAI  5 
PGA2  5 
HSDM1 factor~C  0.2 
HSDM1 factor (ether soluble)§  0.02 
* The extent of bone  resorption was estimated by visual observation of bones at 48-hr 
intervals (for 7-8 days). Resorption was scored on a scale of 0-6, where 0 is no resorption 
and 6 is complete demineralization. A mean index score  (four  bones per group) of 3.0 is a 
half-maximum effect. 
:~ Active fraction from Sephadex G-10 filtration. 
§ Activity from above Sephadex G-10 fraction which was extracted into ether; no detect- 
able residual activity remained in the aqueous phase. 
Effect  of Medium from  Cultures  of HSDMa Cells  on Bone Resorption.--Un- 
cloned HSDM1  cell lines secreted  the bone  resorption-stimulating factor into 
the  culture  medium.  Fig.  3  shows  the  appearance  of  bones  cultured  with 
aliquots of medium from HSDM1 cells. As with extracts of HSDM1 tumor tissue, 
the factor secreted by the cells in culture was extracted into ether (Fig. 3). 
Cultures of HSDM1 cells were cloned and five clonal strains were established. 
Fig.  4  gives  the  appearance  of  clone  1,  HSDM1C1.  HSDM1Cx  cells have  a 
population  doubling  time  of  about  40  hr  and  secrete  the  bone  resorption- 
stimulating factor into  the culture  medium  during  both  the  exponential and 1334  TUMOR  PROSTAGLANDINS  AND  BONE  RESORPTION 
Fro. 3.  Effect of HSDM1 cell culture medium on bone resorption. Control bones are on the 
left. On the far right is shown the effect 0.2 ml of medium which had been on cultured HSDM1 
cells for 3 days. The effect of an ether extract of the same HSDM1 medium (dose equivalent to 
0.2 ml of original medium) is shown in group 4  (ether extract). Effects of parathyroid hormone 
(0.10 units/ml) and of PGE2 (0.01/~g/ml) are also shown. Control medium from five other cell 
lines did not stimulate bone resorption in this assay system. 
FIG. 4.  Apt)earance of HSDM1C1 cells 5 days after subculture.  (Unstained, phase-contrast 
microscopy, one scale division is equal to 0.01  mm.) TASHJIAN,  VOELKEL,  LEVINE,  AND  GOLDHABER  1335 
plateau  phases  of cell  growth  (4).  Using  the  4~Ca-release  bone  culture  assay 
method,  the  results  given  in  Table  II  show  the  stimulation  of 4~Ca release 
induced by medium from HSDMaC~ cells. Similar ether extracts of fresh control 
medium  and  of conditioned  medium  from five  other  tumor  cell  lines  (three 
mouse,  one  rat,  and  one  human)  did  not  stimulate  bone  resorption  or 45Ca 
release. 
In order to show that the  cells which  were cloned were indeed  tumor cells, 
the cultured cells (10 ~ per mouse) were injected into mice. All five injected mice 
developed  tumors within  1 wk. The tumors were removed, extracted,  and the 
extracts  were  assayed  for bone  resorption-stimulating  activity.  Each  extract 
stimulated  bone resorption.  Portions  of the  culture-derived  tumors  were pre- 
pared  for  culture  and  new  dispersed  cell  cultures  were  established.  Each  of 
these second generation cell cultures also secreted the bone resorption-stimulat- 
ing factor into the culture medium. 
TABLE II 
Effects of PTII and Medium .from HSDM1Ct Cells on Bone Resorption 
Treatment  Dose 
45Ca release from bone* 
24 hr  48 hr 
per ml  cpm  X  lO-4/ml medium 
Control  --  1.6  4-  0.36  2.3  4-  0.64 
PTH  0.01  U  2.5  4-  0.36  4.0  4-  0.64 
HSDM1C1 medium:~  0.20 ml  2.8  4-  0.36  4.8  4-  0.64 
* Mean values of four bones per group 4- SE. 
:~ Medium was on HSDMIC1 cells for 4 days. It was extracted  with ether and tested at a 
dose level equivalent to 0.20 ml of original medium. 
Several lines of evidence led us to postulate that the factor produced by the 
HSDMi  tumor  in  vivo and  secreted  by the  tumor  cells  in  vitro  might  be  a 
prostaglandin  (1).  In brief,  the  characteristics  of the  factor which  were  con- 
sistent with this hypothesis were: (a) its low molecular weight (determined  by 
gel filtration,  dialysis,  and  ultracentrifugation;  (b)  its  stability  at  100°C  (pH 
7.5  for  15  min);  (c)  its  resistance  to inactivation  by trypsin  and  pepsin;  (d) 
its  high  specific  biological  activity  (Table  I);  and  (e)  its  solubility  in  ether, 
chloroform, and ethyl acetate. However, before determining whether the tumor 
cells did produce prostaglandins,  we tested several of these cyclic, oxygenated 
C20 fatty acids in the 4~Ca-release assay. Table III shows that PGE1 and PGE2 
stimulate  45Ca  release  at  dose  levels  of  0.01-0.10  ~g/ml.  PGA1  and  PGA.. 
were  about  50-fold  less  active,  and  PGFla,  PGF2a,  PGB1,  and PGB2were 
inactive at  the dose levels tested. 
Assay  of  Medium  from  HSDM1  Cells  for  Prostaglandins.--Media  from 
uncloned and cloned HSDM1 cells and from five control cell lines were assayed 
immunologically  for  prostaglandins.  Based  on  the  results  of  the  serological 
experiments  reported  previously  (4),  the  results  are  expressed  in  terms  of a 1336  TUMOR  PROSTAGLANDINS  AND  BONE  RESORPTION 
TABLE  III 
Effects  of  Various  prostaglandins  on  Bone  Resorption 
Experiment No.  Treatment  Dose 
45Ca release  from bone* 
24 hr  48 hr 
Control 
i~glml  cpm X  10 4/ml medium 
--  1.4  2.1 
PGE~  0.10  3.5+  5.8:~ 
PGE2  0.10  3 ~6:~  6.2:~ 
PGA1  3.0  2.2  3.9 
PGA~  3.0  2.9  4.0 
PGFI~  3.0  1.7  2.8 
PGF2,,  3.0  2.1  3.6 
PGB 1  10.0  2.2  3.5 
PGB2  10.0  2.3  3.4 
II  Control  ---  2.4  3.0 
PGE1  0.10  4.9:~  8.5:~ 
PGE1  0.01  4.7~t  7.0~ 
PGE~  0.05  4.62~  9.0~ 
PGE2  0.005  3.8:~  5.0~ 
III  Control  --  1.5  2.5 
PGE2  0.10  3.6~  6.3~ 
PGA1  5.0  3.4:~  5.4~ 
PGA1  0.5  2.4  4.5 
PGA2  5.0  2.6  5.2:~ 
PGAe  0.5  2.4  4.3 
* Mean values of three or four bones per group. The range of the sE for the three experi- 
ments was ~0.47-0.50 for 24 hr and 0.68-0.91 for 48 hr, respectively. 
~t P  <  0.05 as compared to control 45Ca release. 
PGE2  standard,  Fresh  culture medium contained no  detectabIe  PGE2.  The 
results given in Table IV show  that both uncloned and cloned HSDM1 cells 
produced  PGE2,  while control cells,  which  do  not produce bone resorption- 
stimulating factors,  do  not  produce  measurable  quantities  of  PGE2.  Both 
aqueous  and  ether  extracts  of  HSDM1  tumor  tissue  which  contained bone 
resorption-stimulating activity also contained PGE2 by immunoassay. 
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bone  resorption-stimulating factor and  PGE2.  The  data  in  Tables I  and  III 
and in Fig. 3 show that PGE2 stimulates bone resorption at low dose levels. In 
order  to determine whether PGE2  and  the  bone  resorption-stimulating factor 
were produced in parallel, we took advantage of the finding that indomethacin 
is a potent inhibitor of PGE~ synthesis by HSDM1 cells (4). 
Effect  of Indomethacin  on  the  Production  of PGE2  and  the  Bone  Resorption- 
Stimulating  Factor.--The  data  in  Table  V  show  that  PGE2  production  was 
inhibited by indomethacin.  When HSDM1C1 cells were grown in the presence 
of indomethacin, the medium was also found to lack bone resorption-stimulating 
TABLE IV 
Prostaglandln Production by HSDM1 Cdls in Culture 
Cell type  Prostaglandin production* 
HSDM1  (uncloned) 
I.~g PGE2 per mg cell protein per 24 hr 
1.0~-1.2 
HSDM1CI  2.0 
HSDMIC~  1.2 
HSDMIC3  2.0 
HSDMIC4  0.80 
HSDM1C5  0.72 
Mouse fibroblasts  (Rs)  <0.03 
Mouse neuroblastoma  (41A3)  <0.01 
Mouse adrenal  (AT10)  <0.01 
Rat glial (C6)  <0.01 
Human HeLa  <0.01 
* Medium  samples were 3-day  collections which  were assayed  for  prostaglandins  after 
treatment with alkali as described previously (4, 11). When medium was extracted  with ether 
and assayed serologically, the PGE2 was quantitatively extracted into the ether phase. 
TABLE V 
Effect of Indomethacin on PGE2 Production by HSDMxC1 Cells 
Treatment  Dose  Prostaglandin production* 
ng/ml  #g PGE2 per mg cell protein 
per 24 hr 
Control  --  1.94 
Indomethacin  100  O. 15 
lndomethacin  10  O. 58 
Indomethacin  1.0  0.95 
Indomethacin  O. 10  1.45 
* Medium containing either no additions  (control) or indomethacin was added to replicate 
dishes of HSDM1C1 cells. 3 days later the medium was collected for prostaglandin  assay. The 
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activity  (Table  VI).  Indomethacin  does  not  affect  the bone  culture  assay per 
se, nor does it inhibit the effect of PGE2 on 4SCa release (Table VII). Likewise, 
indomethacin does not affect the growth of HSDM~ cells (4), nor does it cause 
the  cells  to  produce  a  substance  which  inhibits  the  effect  of  PGE2  on  bone 
resorption  (Table  VIII). 
TABLE VI 
Effect of Indomethacin on the Production of the Bone Resorptlon-Stim~dating Factor by 
HSDM1C1 Cells 
Treatment 
45Ca release from bone* 
24 hr  48 hr 
Control 
HSDM1C1 medium:~ 
HSDM1C1 +  indomethacin medium:~ 
cpm X  lO-4/ml medium 
1.8  4-  0.36  2.7  i  0.60 
3.3  -4-  0.36  6.2  4-  0.60 
1.5  4-  0.36  2.2  4-  0.60 
* Mean values of four bones per group ±  SE. 
:~ HSDMIC1 ceils were grown for 4 days in medium without or with indomethacin  (100 
ng/ml). The medium was extracted with ether and tested at a dose level equivalent 0.10 ml 
of original medium for untreated  cells and  0.20  ml of  original  medium  for indomethacin- 
treated cells. 
TABLE  VII 
Effects of Indomethacln on 45Ca Release  from Labeled Bone 
Treatment  Dose 
45Ca release from bone* 
24 hr  48 hr 
ng/ml  cpm X  lO-4/ml medium 
Control  --  2.2  ±  0.34  3.5  4-  0.58 
PGE2~  100  3.0  4-  0.34  5.0  4-  0.58 
Indomethacin:i  500  2.0  4-  0.34  2.9  4-  0.58 
PGE2 +  indomethacin:~  100  +  500  2.9  4-  0.34  5.8  4-  0.58 
* Mean values of four bones per group :t= sE. 
:~ Labeled bones were cultured in control medium or in medium containing PGE 2, indo- 
methacin alone, or PGE2 plus indomethacin at the dose levels shown. 
Effect  of the  HSDM1  Tumor  on  Serum  Calcium  Levels  in  Tumor-Bearing 
Mice.--The  results  in Table IX  show  that  mice bearing HSDM1  tumors  have 
higher  serum  calcium  levels  than  control  mice  (P  <  0.001).  Examination  of 
undecalcified  sections  of  the  long  bones  of  the  extremities  from  10  tumor- 
bearing mice showed no gross or microscopic evidence of metastatic  tumor cell 
deposits. 
Effect of the HSDM1  Tumor on Serum Prostaglandin Levels in Tumor-Bearing 
Mice.--The  data  in  Table  X  show  that  mice  bearing  HSDM1  tumors  have 
levels of PGE2  in  serum  that  are two to three times higher than  control mice. TASHJIAN~ VOELKEL~ LEVINE,  AND  GOLDHABER  1339 
TABLE VIII 
Medium from Indomethacin-Treated  tlSDM1C1  Cells Does Not Inhibit the Effect  of PGE2 on 
Bone Resorption 
Treatment  Dose of PGE2 
45Ca release from b)ne* 
24 hr  48 hr 
ng/ml  cpm X lO 4/ml medium 
Control  --  1.5  2.5 
PGE2  100  3.6  6.2 
PGE2  10  2.8  4.4 
HSDM1C1 +  indomethacin:~  --  1.4  2.0 
HSDM~C1 +  indomethacin +  PGE2  100  4.4  6.8 
HSDM1C1 +  indomethacin +  PGE2  10  2.6  4.6 
* Mean values of four bones per group. The SE for 24 and 48 hr were 4- 0.48  and 0.80, 
respectively. 
:~ HSDMIC1 cells were treated  with indomethacin  (100 ng/ml)  for 3 days and  medium 
collected and  extracted with ether for assay  of bone resorption-stimulating activity either 
without or with added  PGEe. HSDM1C1 medium was tested  at a  dose level equivalent to 
0.10  ml of original medium. 
TABLE  IX 
Serum Calcium  Concentrations in Control and HSDM1 Tumor-Bearing  Mice 
Experiment No.  Treatment  No. of mice  Serum calcium* 
mg/lO0 ml 
I  Control  22  9.6  ±  0.10 
Tumor bearing:~  24  10.3  q-  0.10 
II  Control  23  9.8  4-  0.08 
Tumor bearingS:  35  11.l  4-  0.16 
* Mean values 4- sE. 
~: Animals were bled 18-24 days after inoculation of tumor cells. 
DISCUSSION 
Klein  and  Raisz have  shown  that  prostaglandins  are  potent  stimulators  of 
bone resorption  in  tissue  culture  (14).  This knowledge  together with  our find- 
ing  that  the  transplantable  mouse  fibrosarcoma,  HSDM1,  produced  a  very 
active  bone  resorption-stimulating  factor,  which  was  extracted  into  organic 
solvents,  led us to postulate  that  the HSDM1  factor might be a  prostaglandin 
(1).  HSDM1  tumor  cells were  established  in  culture  and  were  shown  to  syn- 
thesize and secrete large quantities of PGE2  (4). In the present report,  we have 
shown that mice bearing the HSDM1 tumor have higher levels of both calcium 
(Table IX)  and  PGE2  (Table X)  in  serum  than  control mice. In addition,  the 1340  TUMOR  PROSTAGLANDINS AND  BONE  RESORPTION 
HSDM1 cells in culture secrete into the medium the bone resorption-stimulat- 
ing factor which has several chemical and biological properties in common with 
prostaglandins.  The  HSDM1  factor  is  extracted  quantitatively  into  organic 
solvents, it is of low molecular weight, stable at neutral pH at 100°C, resistant 
to inactivation by trypsin and pepsin, and active in enhancing bone resorption 
in vitro at submicrogram per milliliter quantities, comparable to those of PGE2 
(Table III). We have tested five other lines of tumor cells in culture which do 
not  produce  prostaglandins,  and  none  of  these  produce  a  bone  resorption- 
stimulating  factor.  Lastly,  indomethacin,  which  inhibits  PGE2  synthesis  in 
TABLE X 
Levels of PG1Q in the Serum of Control and IISDM1  Tumor-Bearing  Mice 
Experiment No.  Treatment  Serum PGE:~ 
pg/ml 
I*  Control  245  ~  35 
II:~  Control  185 
Tumor-bearing 1  680 
Tumor-bearing 2  520 
Tumor-bearing 3  500 
Tumor-bearing 4  500 
III,  Control  275 
Tumor-bearing 1  720 
Tumor-bearing 2  840 
* Mean value +  sE; six separate pools of control sera; each pool was derived from 5-10 
mice. 
:~ Each value is the mean of duplicate determinations of a separate pool of serum from 
6-20 control or tumor-bearing mice. 
HSDM1 cells  at low concentrations (50 % inhibition  at  1 ng/ml, 3  X  10  -" ?¢) 
(Table V),  also  inhibits  production of the  bone resorption-stimulating  factor 
(Tables VI and VIII). At the dose levels  used, indomethacin does not inhibit 
cell growth or protein synthesis in HSDM1 cells (4). Furthermore, indomethacin 
does not inhibit nonspecifically the effects of PGE2 or cause the HSDM1 cells 
to produce an inhibitor of bone resorption in vitro (Tables VII and VIII). 
From the results of these experiments, we conclude that the bone resorption- 
stimulating  factor  produced  by  HSDM1  cells  is  PGE~.  Furthermore,  we 
believe that secretion of PGE2 by the tumor in vivo can explain the elevated 
levels of this prostaglandin measured in serum and  the  relative hypercalcemia 
which  tumor-bearing mice exhibit. 
Klein and Raisz (14)  and ourselves have not been  able to show a  calcium- TASHJIAN,  VOELKEL,  LEVINE,  AND  GOLDHA:BER  1341 
mobilizing effect of PGE1 or PGE2 (up to 500/~g/rat, subcutaneously) in intact 
or parathyroidectomized rats. The experiment has not yet been done in mice. 
Failure to observe an effect of a single injection in vivo may well be explained 
by the rapid metabolism and clearance from plasma known to exist for PGE 
in the whole animal. On the other hand, the constant high secretory rate of the 
HSDM1 tumor might give rise to levels of PGE2 in plasma which were suf- 
ficiently high for a sufficient period to enhance bone resorption in vivo. 
The HSDM1  tumor and  cell  culture  systems  constitute useful  models for 
studying the effects of prostaglandin excess in vivo and in vitro. These findings 
may even offer an explanation for some of the previously unexplained hyper- 
calcemias  associated  with  malignant  tumors  in  man.  The syndrome or syn- 
dromes of hypercalcemia in patients with cancer in whom no bone metastases 
are  evident is  not  uncommon  (15).  Some  of  these  tumors  synthesize PTH 
(15-18) and this may explain the hypercalcemia in those patients. However, in 
other  cases,  with  what  appears  to  be  a  similar  tumor-induced  syndrome, 
PTH has not been measured in excess in plasma or tumor tissue (15-19). We 
would postulate that the etiology of the hypercalcemia in some of these cases 
could be due to the synthesis and secretion of large quantities of prostaglandins, 
presumably PGE,  by the  tumor.  It  has  already been  reported in  man,  for 
example, that some medullary carcinomas of the thyroid gland secrete prosta- 
glandins  (20);  and  two  experimental  tumors  have  recently been  shown  to 
contain measurable quantities of intracellular prostaglandins (21). The availa- 
bility of sensitive radioimmunoassay methods for prostaglandins  should now 
make it possible to test this hypothesis. If confirmed in clinical studies, these 
results suggest that indomethacin or related drugs which inhibit prostaglandin 
synthesis might prove beneficial in the medical management of prostaglandin- 
induced bypercalcemia. 
SUMMARY 
A  transplantable  mouse  fibrosarcoma,  HSDM1,  produces  a  potent  bone 
resorption-stimulating  factor.  The  factor can  be  extracted  from  the  tumor 
tissue and harvested from the medium of clonal strains of HSDM1 tumor cells 
growing in monolayer culture. It has several chemical and biological properties 
of a prostaglandin.  Using radioimmunoassay techniques, we have shown that 
HSDM1  cells  synthesize  and  secrete  large  quantities  of  prostaglandin  E2 
(PGE2).  The  specific  bone  resorption-stimulating  activity  of  the  HSDMI 
factor extracted from the  tumor is  high  and  approximately equal to that  of 
PGE2 as measured in a bone tissue culture system in vitro. Indomethacin, a 
potent inhibitor of PGE2 synthesis in HSDM1 cells, also inhibits production by 
the  cells  of  the  bone  resorption-stimulating  factor,  and  has  no  detectable 
nonspecific effects on the bone culture assay system. Mice bearing the HSDM1 
tumor have higher  levels of both  calcium and  PGE2 in  serum  than  control 
mice. We conclude that  PGE2 is  the bone resorption-stimulating factor pro- 1342  TU~IOR  PROSTAGLANDINS AND  BONE  RESORPTION 
duced by HSDM1 tumor ceils, and that secretion of PGE2 by the tumor in vivo 
accounts  for  the  relative hypercalcemia  observed  in  tumor-bearing  animals. 
The  HSDM1  tumor  cell  system  constitutes  a  new  model  for  studying  the 
pathogenesis of hypercalcemia associated with certain malignant tumors. 
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